Pioglitazone Metformin Complex Improves Polycystic Ovary Syndrome Comorbid Psychological Distress via Inhibiting NLRP3 Inflammasome Activation: A Prospective Clinical Study

Objective. This study aimed at investigating the therapeutic effect and mechanism of pioglitazone metformin complex preparation (PM) in polycystic ovary syndrome (PCOS) comorbid psychological distress. Methods. Seventy-five patients with PCOS comorbid psychological distress were randomly allocated i...

Full description

Saved in:
Bibliographic Details
Main Authors: Qing-jun Guo (Author), Jing Shan (Author), Yi-feng Xu (Author), Yan-yan Hu (Author), Cui-lan Huo (Author), Jing-yun Song (Author), Chao-qun Wang (Author), Hui Zhou (Author), Chao-qin Yu (Author), Qin Huang (Author)
Format: Book
Published: Hindawi Limited, 2020-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_ba80a2d3cfe040cd9a7c0a3ab3a3350e
042 |a dc 
100 1 0 |a Qing-jun Guo  |e author 
700 1 0 |a Jing Shan  |e author 
700 1 0 |a Yi-feng Xu  |e author 
700 1 0 |a Yan-yan Hu  |e author 
700 1 0 |a Cui-lan Huo  |e author 
700 1 0 |a Jing-yun Song  |e author 
700 1 0 |a Chao-qun Wang  |e author 
700 1 0 |a Hui Zhou  |e author 
700 1 0 |a Chao-qin Yu  |e author 
700 1 0 |a Qin Huang  |e author 
245 0 0 |a Pioglitazone Metformin Complex Improves Polycystic Ovary Syndrome Comorbid Psychological Distress via Inhibiting NLRP3 Inflammasome Activation: A Prospective Clinical Study 
260 |b Hindawi Limited,   |c 2020-01-01T00:00:00Z. 
500 |a 0962-9351 
500 |a 1466-1861 
500 |a 10.1155/2020/3050487 
520 |a Objective. This study aimed at investigating the therapeutic effect and mechanism of pioglitazone metformin complex preparation (PM) in polycystic ovary syndrome (PCOS) comorbid psychological distress. Methods. Seventy-five patients with PCOS comorbid psychological distress were randomly allocated into the PM, metformin, and placebo groups. The primary efficacy measure was the change from baseline to week 12 on the Symptom Checklist 90-R (SCL-90-R) scores. NLRP3 inflammasome, IL-1β, IL-6, TNF-α, and biochemical parameters were determined at baseline and at week 12. The participants were required to meet the criteria for PCOS (Rotterdam, NIH) and psychological distress (any factor scores of SCL−90−R>2). Results. The participants had significantly high scores on the SCL-90-R scales of anxiety and depression. PM significantly decreased anxiety and depression symptom severity (from 2.31±0.75 to 1.65±0.38, p<0.001, and from 2.08±0.74 to 1.61±0.46, p=0.010, at week 12, respectively). PM significantly decreased the expression of NRPL3 and caspase-1. Patients in the PM group experienced a significant reduction in IL-1β (from 98.42±14.38 to 71.76±13.66, p=0.02), IL-6 (from 87.51±8.74 to 71.98±15.87, p=0.02), and TNF-α (from 395.33±88.55 to 281.98±85.69, p=0.04). PM was superior to metformin in reducing total testosterone (2.24±0.74 versus 3.06±0.83, p=0.024, at week 12).Conclusions. This study is the first to reveal that PM alleviates psychological distress via inhibiting NLRP3 inflammasome and improves several markers, including total testosterone. 
546 |a EN 
690 |a Pathology 
690 |a RB1-214 
655 7 |a article  |2 local 
786 0 |n Mediators of Inflammation, Vol 2020 (2020) 
787 0 |n http://dx.doi.org/10.1155/2020/3050487 
787 0 |n https://doaj.org/toc/0962-9351 
787 0 |n https://doaj.org/toc/1466-1861 
856 4 1 |u https://doaj.org/article/ba80a2d3cfe040cd9a7c0a3ab3a3350e  |z Connect to this object online.